China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a memorandum of understanding (MOU) with South Korea-headquartered Boostimmune. This collaboration focuses on research and discovery services related to Boostimmune’s innovative pipelines.
Under this agreement, WuXi Bio will serve as Boostimmune’s exclusive research and development service partner. The partnership aims to support the development of monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and recombinant proteins. Specific financial details of the arrangement have not been disclosed.
Founded in 2021, Boostimmune is dedicated to developing first-in-class antibodies to meet cancer treatment needs. Its product pipeline includes mAbs designed to regulate the tumor immune microenvironment, biomarker antibody-drug conjugates (ADCs), and immune-stimulating antibody conjugates (ISACs) that directly target immunosuppressive bone marrow cells.-Fineline Info & Tech
